Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.63 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.54 |
| ▸ | MIF | P14174 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ESRRA | P11474 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17883261 | 0.84 | RIPK1 (0.63) | RIPK1ACKR3MIFGLAESRRA | |
| SCHEMBL30009481 | 0.82 | RIPK1 (0.63) | RIPK1ACKR3MIFSMN1; SMN2NPC1 | |
| SCHEMBL21635351 | 0.81 | RIPK1 (0.56) | RIPK1ACKR3MIFESRRA | |
| SCHEMBL28542983 | 0.81 | RIPK1 (0.56) | RIPK1ACKR3MIFESRRA | |
| SCHEMBL73126 | 0.81 | RIPK1 (0.62) | RIPK1ACKR3MIFESRRAL3MBTL1 | |
| SCHEMBL17883253 | 0.77 | RIPK1 (0.58) | RIPK1ACKR3MIFNPC1ESRRA | |
| SCHEMBL23525601 | 0.76 | RIPK1 (0.46) | RIPK1ACKR3MIF | |
| SCHEMBL28535504 | 0.76 | RIPK1 (0.46) | RIPK1ACKR3MIF | |
| SCHEMBL24784760 | 0.76 | ESRRA (0.55) | RIPK1NPC1GLAESRRAL3MBTL1 | |
| SCHEMBL23525611 | 0.75 | RIPK1 (0.46) | RIPK1ACKR3MIFESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738011-B2 | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2016105484-A1 | DERIVATIVES OF 5-(HETERO)ARYLPYRAZOL-3-CARBOXYLIC AMIDE OR 1-(HETERO)ARYLTRIAZOL-4-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738011-B2 | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis | CFTR, SLC33A1, SLC26A4 | RIPK1 2731/4885ACKR3 1560/4885MIF 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.